Loading
Life sciences · Journal article
Clinica Chimica Acta; International Journal of Clinical Chemistry · August 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background. Early detection of Alzheimer's disease (AD) necessitates affordable and accessible blood biomarkers. Plasma phosphorylated tau 217 (P-tau217) is promising, but low-cost platforms for large-scale screening remain limited.Methods. We validated a Digital Single-Molecule Sensing (DiSMS) platform for plasma P-tau217 quantification. A reference interval was established in Cohort I (discovery, n = 325, comprising 143 cognitively unimpaired controls, 80 CE, 34 frontotemporal dementia [FTD], and 68 subcortical ischemic vascular dementia [SIVD] patients). Diagnostic performance was validated in Cohort II (n = 242; 77 CE, 165 controls). Cross-platform concordance was assessed against the Simoa HD-X in 137 paired samples.Results. The healthy reference interval was 0.09-0.51 pg/mL. In Cohort II, P-tau217 strongly distinguished AD from controls (accuracy 93.4% [95% CI: 90.3%-96.5%], sensitivity 92.2% [95% CI: 83.2%-96.8%], specificity 93.9% [95% CI: 88.8%-96.9%]). A two-cutoff approach (< 0.40, 0.40-0.50, > 0.50 pg/mL) yielded 94.1% accuracy and 95.9% sensitivity, leaving 8.4% of cases in the intermediate zone. DiSMS exhibited strong concordance with the Simoa (concordance rate = 94.9%; Spearman r = 0.94, P < 0.001). Plasma P-tau217 was significantly higher in AD than FTD (median 0.25 pg/mL) and SIVD (median 0.36 pg/mL) (both P < 0.001). Age-adjusted AUC was moderate for AD versus SIVD (0.777) but limited for AD versus FTD (0.665; sensitivity/specificity below 65%).Conclusions. The DiSMS platform enables accurate, cost-accessible plasma P-tau217 quantification for AD screening, meeting consensus guidelines (≥90%). The limited P-tau217 performance for differentiating AD from FTD (AUC = 0.665) highlights the need for integration with complementary biomarkers or clinical assessments.